It is evident from our data that the resminostat/ruxolitinib drug combination affects the activation of Akt and JNK in both cell lines, whereas it also inhibits JAK/STAT and MAPK activation in MF cell line, a finding that further indicates the differential genetic and epigenetic mechanisms implicated in MF and SS. The gene discussed is MAPK8; the disease is mycosis fungoides.